Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2024-08-27 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
2024年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "东北制药集团股份有限公司2024 年半年度财务报告" which translates to "Northeast Pharmaceutical Group Co., Ltd. 2024 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2024. The report explicitly states it is a half-year (semi-annual) financial report and includes comprehensive financial data and analysis. It is not an announcement or a brief summary but a full financial report for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-27 Chinese
关于召开公司2024年第二次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the company's 2024 second extraordinary general meeting of shareholders (临时股东大会). It includes details about the meeting date, voting procedures, agenda items, and proxy forms. It does not contain financial statements or results but is an announcement related to a shareholders meeting. The document length is 3850 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it is best classified as a Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings.
2024-08-27 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2024 年半年度报告摘要' which translates to '2024 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, total assets, and shareholder information for the half-year period. The document includes accounting data comparisons with the previous year and discusses business activities and shareholder structure. The length is about 2738 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary notice. The content matches the characteristics of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes actual financial statements and analysis. Therefore, the correct classification is 'IR'. H1 2024
2024-08-27 Chinese
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 30th meeting of the 9th Board of Directors of Northeast Pharmaceutical Group Co., Ltd. It includes details about the meeting date, attendance, voting results on various proposals, and references to other announcements and reports (such as the 2024 semi-annual report and notices about shareholder meetings). The document does not contain the actual semi-annual report or detailed financial data but rather announces the board meeting decisions and references other filings for detailed content. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short (1103 characters), and it is not a full financial report or earnings release. Therefore, the appropriate classification is MANG with high confidence.
2024-08-27 Chinese
关于股价异动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding abnormal stock price fluctuations and the company's explanation about a proposed acquisition of a 70% stake in another company. It includes risk warnings, financial data of the target company, and confirms no undisclosed material information exists. The document references a previously disclosed acquisition framework agreement and mentions an upcoming half-year report but does not contain actual financial statements or detailed financial analysis itself. The length is relatively short (2485 characters) and the content is focused on disclosure and compliance related to stock price movements and acquisition intentions rather than a full financial report or earnings release. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2024-08-08 Chinese
关于签署股权收购框架协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Dongbei Pharmaceutical Group Co., Ltd. regarding the signing of a framework agreement for an equity acquisition. It details the intention to acquire 70% equity of Beijing Dingcheng Taiyuan Biotechnology Co., Ltd., including the transaction overview, parties involved, company background, and the approval process by the board of directors. The document does not contain financial statements or detailed financial performance data but rather focuses on the transaction announcement and related corporate governance procedures. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a proxy solicitation or voting result announcement. The document fits the category of Capital/Financing Update (CAP) as it provides an update on a significant financing activity (equity acquisition) and related corporate actions.
2024-08-05 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.